Expert Interview
Discussing the results from Edgewise Therapeutics ARCH study of EDG-5506, a myofiber type II myosin inhibitor for patients with Becker Muscular Dystrophy (BMD).
Ticker(s): EWTXInstitution: Duke University
- Assistant Professor in the Department of Pediatrics, Division of Neurolgy at Duke University. Co-Director of Duke Children's Neuromuscular Program
- Manages 20 patients with Becker Muscular Dystrophy
- Research interest in Duchenne Muscular Dystrophy, spinal muscular dystrophy, and other rare forms of neuromuscular disease including Becker Muscular Dystrophy.
Describe your background and practice setting
Added By: ben_adminHow many patients with BMD do you manage?
Added By: ben_adminWhat are your takeaways from the open label ARCH study of EDG-5506?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
